Mechanisms and Diagnostic Implications
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
F8A2 Antibody (N-Term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap11393a
苏州工业园区双圩路9号1幢 邮 编 : 215000 电 话 : 0512-88856768 F8A2 Antibody (N-term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP11393a Specification F8A2 Antibody (N-term) - Product info Application WB Primary Accession P23610 Other Accession NP_001007525.1, NP_001007524.1, NP_036283.2 Reactivity Human Host Rabbit Clonality Polyclonal Isotype Rabbit IgG Clone Names RB29381 F8A2 Antibody (N-term) - Additional info Gene ID 474383;474384;8263 F8A2 Antibody (N-term) (Cat. Other Names #AP11393a) western blot analysis in CEM Factor VIII intron 22 protein, CpG island protein, F8A1, F8A cell line lysates (35ug/lane).This demonstrates the F8A2 antibody Target/Specificity detected the F8A2 protein (arrow). This F8A2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 12-40 amino acids from the N-terminal region of human F8A2. Dilution WB~~1:1000 Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. Precautions F8A2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. F8A2 Antibody (N-term) - Protein Information Name F8A1 Function RAB5A effector molecule that is involved in vesicular trafficking of early endosomes (PubMed:<a href="http://www.uniprot.org/citations/16476778" target="_blank">16476778</a>). Mediates the recruitment of HTT by RAB5A onto early endosomes. The HTT- F8A1/F8A2/F8A3-RAB5A complex stimulates early endosomal interaction with actin filaments and inhibits interaction with microtubules, leading to the reduction of endosome motility (PubMed:<a href="http://www.uniprot.org/citations/16476778" target="_blank">16476778</a>). -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
Downloaded from [266]
Patterns of DNA methylation on the human X chromosome and use in analyzing X-chromosome inactivation by Allison Marie Cotton B.Sc., The University of Guelph, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in The Faculty of Graduate Studies (Medical Genetics) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) January 2012 © Allison Marie Cotton, 2012 Abstract The process of X-chromosome inactivation achieves dosage compensation between mammalian males and females. In females one X chromosome is transcriptionally silenced through a variety of epigenetic modifications including DNA methylation. Most X-linked genes are subject to X-chromosome inactivation and only expressed from the active X chromosome. On the inactive X chromosome, the CpG island promoters of genes subject to X-chromosome inactivation are methylated in their promoter regions, while genes which escape from X- chromosome inactivation have unmethylated CpG island promoters on both the active and inactive X chromosomes. The first objective of this thesis was to determine if the DNA methylation of CpG island promoters could be used to accurately predict X chromosome inactivation status. The second objective was to use DNA methylation to predict X-chromosome inactivation status in a variety of tissues. A comparison of blood, muscle, kidney and neural tissues revealed tissue-specific X-chromosome inactivation, in which 12% of genes escaped from X-chromosome inactivation in some, but not all, tissues. X-linked DNA methylation analysis of placental tissues predicted four times higher escape from X-chromosome inactivation than in any other tissue. Despite the hypomethylation of repetitive elements on both the X chromosome and the autosomes, no changes were detected in the frequency or intensity of placental Cot-1 holes. -
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0299658 A1 Hekele Et Al
US 20200299658A1 INI ( 19 ) United States ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0299658 A1 Hekele et al . ( 43 ) Pub . Date : Sep. 24 , 2020 ( 54 ) ENGINEERED NUCLEASES THAT TARGET C12N 5/071 ( 2006.01 ) HUMAN AND CANINE FACTOR VIII GENES C12N 15/113 ( 2006.01 ) AS A TREATMENT FOR HEMOPHILIA A A61K 48/00 ( 2006.01 ) ( 71 ) Applicant: Precision BioSciences , Inc. , Durham , A61K 9/127 ( 2006.01 ) NC (US ) ( 52 ) U.S. CI . CPC ( 72 ) Inventors : Armin Hekele , Cary, NC ( US ) ; C12N 9/22 ( 2013.01 ) ; C12N 15/86 Clayton Beard , Durham , NC ( US ) ; ( 2013.01 ) ; C12N 5/067 ( 2013.01 ) ; C12N Derek Jantz , Durham , NC (US ); James 570672 ( 2013.01 ) ; C12N 15/113 ( 2013.01 ) ; Jefferson Smith , Morrisville , NC ( US ) ; A61K 38/02 ( 2013.01 ) ; A61K 9/127 ( 2013.01 ) ; Victor Bartsevich , Durham , NC (US ) C12N 2750/14143 ( 2013.01 ) ; C12N 2310/20 ( 73 ) Assignee : Precision BioSciences , Inc. , Durham , ( 2017.05 ) ; CI2N 2800/80 ( 2013.01 ) ; A61K NC (US ) 48/005 ( 2013.01 ) ( 21 ) Appl. No .: 16 / 760,902 ( 57 ) ABSTRACT ( 22 ) PCT Filed : Nov. 1 , 2018 The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within ( 86 ) PCT No .: PCT / US2018 / 058692 the int22h - 1 sequence of a Factor VIII gene . The present $ 371 ( c ) ( 1 ), invention also encompasses methods of using such engi ( 2 ) Date : Apr. 30 , 2020 neered nucleases to make genetically -modified cells , and the use of such cells in a pharmaceutical composition and in Related U.S. Application Data methods for treating hemophilia A. Further, the invention ( 60 ) Provisional application No. -
Histone H2A Bbd (H2AFB1) (NM 001017990) Human Recombinant Protein Product Data
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP316020 Histone H2A Bbd (H2AFB1) (NM_001017990) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human H2A histone family, member B1 (H2AFB1) Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 12.5 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_001017990 Locus ID: 474382 UniProt ID: P0C5Y9 RefSeq Size: 517 Cytogenetics: Xq28 RefSeq ORF: 345 Synonyms: H2A.B; H2A.Bbd; H2AFB1 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Histone H2A Bbd (H2AFB1) (NM_001017990) Human Recombinant Protein – TP316020 Summary: Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. Nucleosomes consist of approximately 146 bp of DNA wrapped around a histone octamer composed of pairs of each of the four core histones (H2A, H2B, H3, and H4). -
Charakterisierung Der Interaktion Der Merkelzell-Polyomavirus Kodierten T-Antigene Mit Dem Wirtsfaktor Kap1 Svenja Siebels
Charakterisierung der Interaktion der Merkelzell-Polyomavirus kodierten T-Antigene mit dem Wirtsfaktor Kap1 DISSERTATION zur Erlangung des Doktorgrades (Dr. rer. nat.) an der Fakultät für Mathematik, Informatik und Naturwissenschaften Fachbereich Biologie der Universität Hamburg vorgelegt von Svenja Siebels Hamburg, Juli 2018 Gutachter: Prof. Dr. Nicole Fischer Prof. Dr. Thomas Dobner Disputation: 19. Oktober 2018 Für meine Familie. Zusammenfassung Das Merkelzell-Polyomavirus (MCPyV) ist nachweislich für ca. 80 % aller Merkelzellkarzinome (Merkel cell carcinoma (MCC)) verantwortlich. Das virale Genom ist dabei monoklonal in die DNA der Wirtszelle integriert und trägt zusätzlich charakteristische Mutationen im T-Lokus. Das MCPyV kodiert wie alle Polyomaviren (PyV) die Tumor-Antigene (T-Ag) Large T-Ag und small T-Ag, die transformierende Eigenschaften besitzen. Dennoch sind viele Fragen zur MCC-Entstehung weiterhin ungeklärt. Insbesondere die Ursprungszelle, aus der das MCC hervorgeht, ist ungewiss. Das unvollständige Wissen um den viralen Lebenszyklus sowie die kontroversen Modelle hinsichtlich des Reservoirs des Virus erschweren zusätzlich das Verständnis zur Tumorentstehung. Um das transformierende Potential des MCPyV LT-Ags zu beleuchten, wurden vor Beginn dieser Arbeit neue zelluläre Interaktionspartner des LT-Ags mithilfe von Tandem-Affinitäts-Aufreinigung und anschließender multidimensionaler Protein-Interaktions-Technologie (MudPIT) identifiziert (M. Czech-Sioli, Manuskript in Arbeit). Unter den Kandidaten befand sich das Chromatin-modifizierende Protein, Zellzyklusregulator und Korepressor Kap1 (KRAB-associated protein 1) als putativer Interaktionspartner des LT-Ags. Die Interaktion des LT-Ags, sT-Ags und des verkürzten tLT-Ags (tLT-Ags) mit dem Wirtsfaktor Kap1 wurde in dieser Arbeit mithilfe von Koimmunpräzipitationen in unterschiedlichen Tumorzelllinien bestätigt. Weiterhin wurde die Bindung des LT-Ags an Kap1 auf den N-Terminus des LT-Ags und die RBCC-Domäne von Kap1 eingegrenzt. -
Literature Mining Sustains and Enhances Knowledge Discovery from Omic Studies
LITERATURE MINING SUSTAINS AND ENHANCES KNOWLEDGE DISCOVERY FROM OMIC STUDIES by Rick Matthew Jordan B.S. Biology, University of Pittsburgh, 1996 M.S. Molecular Biology/Biotechnology, East Carolina University, 2001 M.S. Biomedical Informatics, University of Pittsburgh, 2005 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2016 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Rick Matthew Jordan It was defended on December 2, 2015 and approved by Shyam Visweswaran, M.D., Ph.D., Associate Professor Rebecca Jacobson, M.D., M.S., Professor Songjian Lu, Ph.D., Assistant Professor Dissertation Advisor: Vanathi Gopalakrishnan, Ph.D., Associate Professor ii Copyright © by Rick Matthew Jordan 2016 iii LITERATURE MINING SUSTAINS AND ENHANCES KNOWLEDGE DISCOVERY FROM OMIC STUDIES Rick Matthew Jordan, M.S. University of Pittsburgh, 2016 Genomic, proteomic and other experimentally generated data from studies of biological systems aiming to discover disease biomarkers are currently analyzed without sufficient supporting evidence from the literature due to complexities associated with automated processing. Extracting prior knowledge about markers associated with biological sample types and disease states from the literature is tedious, and little research has been performed to understand how to use this knowledge to inform the generation of classification models from ‘omic’ data. Using pathway analysis methods to better understand the underlying biology of complex diseases such as breast and lung cancers is state-of-the-art. However, the problem of how to combine literature- mining evidence with pathway analysis evidence is an open problem in biomedical informatics research. -
WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
Differential Expression of COVID-19-Related Genes in European Americans and African Americans
bioRxiv preprint doi: https://doi.org/10.1101/2020.06.09.143271; this version posted June 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Differential expression of COVID-19-related genes in European Americans and African Americans Urminder Singh1 and Eve Syrkin Wurtele1,* 1Bioinformatics and Computational Biology Program, Center for Metabolic Biology, and Department of Genetics Development and Cell Biology, Iowa State University, Ames, IA, 50011, USA *[email protected] ABSTRACT The Coronavirus disease 2019 (COVID-19) pandemic has affected African American populations disproportionately in regards to both morbidity and mortality. A multitude of factors likely account for this discrepancy. Gene expression represents the interaction of genetics and environment. To elucidate whether levels of expression of genes implicated in COVID-19 vary in African Americans as compared to European Americans, we re-mine The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) RNA-Seq data. Multiple genes integral to infection, inflammation and immunity are differentially regulated across the two populations. Most notably, F8A2 and F8A3, which encode the HAP40 protein that mediates early endosome movement in Huntington’s Disease, are more highly expressed by up to 24-fold in African Americans. Such differences in gene expression can establish prognostic signatures and have critical implications for precision treatment of diseases such as COVID-19. We advocate routine inclusion of information such as postal code, education level, and profession (as a proxies for socioeconomic condition) and race in the metadata about each individual sampled for sequencing studies. -
Chew Et Al-2021-Nature Communi
Short H2A histone variants are expressed in cancer Guo-Liang Chew, Marie Bleakley, Robert Bradley, Harmit Malik, Steven Henikoff, Antoine Molaro, Jay Sarthy To cite this version: Guo-Liang Chew, Marie Bleakley, Robert Bradley, Harmit Malik, Steven Henikoff, et al.. Short H2A histone variants are expressed in cancer. Nature Communications, Nature Publishing Group, 2021, 12 (1), pp.490. 10.1038/s41467-020-20707-x. hal-03118929 HAL Id: hal-03118929 https://hal.archives-ouvertes.fr/hal-03118929 Submitted on 22 Jan 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ARTICLE https://doi.org/10.1038/s41467-020-20707-x OPEN Short H2A histone variants are expressed in cancer Guo-Liang Chew 1, Marie Bleakley2, Robert K. Bradley 3,4,5, Harmit S. Malik4,6, Steven Henikoff 4,6, ✉ ✉ Antoine Molaro 4,7 & Jay Sarthy 4 Short H2A (sH2A) histone variants are primarily expressed in the testes of placental mammals. Their incorporation into chromatin is associated with nucleosome destabilization and modulation of alternate splicing. Here, we show that sH2As innately possess features similar to recurrent oncohistone mutations associated with nucleosome instability. Through 1234567890():,; analyses of existing cancer genomics datasets, we find aberrant sH2A upregulation in a broad array of cancers, which manifest splicing patterns consistent with global nucleosome destabilization. -
Insight Into the Function of X-Linked Lymphocyte Regulated 3 (XLR3)
University of Connecticut OpenCommons@UConn Doctoral Dissertations University of Connecticut Graduate School 7-16-2015 Insight into the Function of X-linked Lymphocyte Regulated 3 (XLR3) and the Mechanism Regulating its Imprinted Expression Robert James Foley University of Connecticut - Storrs, [email protected] Follow this and additional works at: https://opencommons.uconn.edu/dissertations Recommended Citation Foley, Robert James, "Insight into the Function of X-linked Lymphocyte Regulated 3 (XLR3) and the Mechanism Regulating its Imprinted Expression" (2015). Doctoral Dissertations. 845. https://opencommons.uconn.edu/dissertations/845 Insight into the Function of X‐linked Lymphocyte Regulated 3 (XLR3) and the Mechanism Regulating its Imprinted Expression Robert J. Foley University of Connecticut 2015 The Synaptonemal Complex Protein 3 (SYCP3), a key component of the synaptonemal complex in mammalian meiosis, has many closely related X‐linked homologs on the X chromosome of which the functions are unclear. In rodentia, these genes comprise the Xlr superfamily of proteins and studies elucidating spatial and temporal profiles of these homologs reveal primarily testis specific function. The following study provides evidence for murine testis and ovary function of a newly discovered Xlr superfamily protein, X‐linked Lymphocyte Regulated 3 (XLR3). In addition to showing the immunolocalization of the XLR3 protein at the condensed X and Y chromosomes throughout Meiotic Sex Chromosome Inactivation (MSCI), preliminary experiments behind the mechanism controlling expression of the imprinted Xlr3b/4b/4c copies reveals a differentially methylated region (DMR) in the adjacent single copy Factor 8 associated gene A (F8a) consistent with differential binding of the master regulator of chromatin conformation factor CTCF. -
Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham a Thesis Submitted in Conformity
Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Molecular Genetics University of Toronto © Copyright by Edward James Higginbotham 2020 i Abstract Characterizing Genomic Duplication in Autism Spectrum Disorder Edward James Higginbotham Master of Science Graduate Department of Molecular Genetics University of Toronto 2020 Duplication, the gain of additional copies of genomic material relative to its ancestral diploid state is yet to achieve full appreciation for its role in human traits and disease. Challenges include accurately genotyping, annotating, and characterizing the properties of duplications, and resolving duplication mechanisms. Whole genome sequencing, in principle, should enable accurate detection of duplications in a single experiment. This thesis makes use of the technology to catalogue disease relevant duplications in the genomes of 2,739 individuals with Autism Spectrum Disorder (ASD) who enrolled in the Autism Speaks MSSNG Project. Fine-mapping the breakpoint junctions of 259 ASD-relevant duplications identified 34 (13.1%) variants with complex genomic structures as well as tandem (193/259, 74.5%) and NAHR- mediated (6/259, 2.3%) duplications. As whole genome sequencing-based studies expand in scale and reach, a continued focus on generating high-quality, standardized duplication data will be prerequisite to addressing their associated biological mechanisms. ii Acknowledgements I thank Dr. Stephen Scherer for his leadership par excellence, his generosity, and for giving me a chance. I am grateful for his investment and the opportunities afforded me, from which I have learned and benefited. I would next thank Drs.